×
ACR 2020 General Meeting Information
https://www.rheumatology.org/Annual-Meeting/Resources/General-Meeting-Information

ACR Convergence, the American College of Rheumatology’s 2020 annual meeting will be in Washington, D.C. November 6 - 11.

ACR/ARHP 2020 American College of Rheumatology Annual Meeting 2020
https://acr-arhp2020.org/

American College of Rheumatology Annual Meeting 2020 06-11 November 2020 Washington DC.

ACR 2020 Abstract Embargo Policies
https://www.rheumatology.org/Annual-Meeting/Abstracts/Embargo-Policies

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new ...

ACR 2020 Online Program
https://plan.core-apps.com/tristar_acr20/customScreen/aboutACR20Program

The Online Program is your source for educational content and program information for the 2020 ACR/ARP Annual Meeting. Look for topics of interest, bookmark sessions, and/or create a customized itinerary. Use the navigation menu to browse sessions, faculty, abstracts, and other meeting content. You can also use the advanced search tool to find sessions.

ACR 2020 Contacts
https://www.rheumatology.org/Annual-Meeting/Resources/Annual-Meeting-Contacts

Registration and Hotels, Education, Abstracts, Exhibits, Press

ACR 2020 Abstracts
https://www.rheumatology.org/Annual-Meeting/Abstracts

Submission, presentation, permission/reprints, embargo, ACR Convergence Awards

ACR 2020 Program
https://www.rheumatology.org/Annual-Meeting/Program

The program has hundreds of sessions to educate professionals in every segment of rheumatology.

ACR 2020 Image Competition Guidelines & Procedures PDF
https://www.rheumatology.org/Portals/0/Files/Image-Competition-Guidelines.pdf

The American College of Rheumatology (ACR) and the Association of Rheumatology Professionals(ARP) invite you to submit a case-based image and take advantage of the opportunity to have your work peer-reviewed by experts in the field. If accepted, your image will be digitally displayed in the distinguished international venue of ACR Convergence 2020 and be added to the ACR Rheumatology Image Libr...

ACR 2020 Image Competition
https://www.rheumatology.org/Annual-Meeting/Program/Image-Competition

Call for Images, Submission Eligibility, Timeline, Permissions

Be proactive in fracture prevention
https://www.mdedge.com/rheumatology/article/214488/osteoporosis/be-proactive-fracture-prevention?channel=53
Elizabeth Shane, MD

Dec 18th, 2019 - Several studies published over the last few years have shown declining rates of diagnosis and treatment of osteoporosis in older adults. In part, this may be due to declining ability to diagnose osteoporosis because declining reimbursement for dual x-ray absorptiometry has made it less available to patients and doctors.

Osteoporotic fracture risk is undermanaged in older adults
https://www.mdedge.com/internalmedicine/article/214483/osteoporosis/osteoporotic-fracture-risk-undermanaged-older-adults?channel=290
Heidi Splete

Dec 18th, 2019 - Treatment of osteoporosis in older adults at increased risk for fractures declined from 2010 to 2014, based on a study of nearly 900,000 individuals. Courtesy University of Alabama at Birmingham Dr.

Well-tolerated topical capsaicin formulation reduces knee OA pain
https://www.mdedge.com/internalmedicine/article/214467/osteoarthritis/well-tolerated-topical-capsaicin-formulation-reduces?channel=290
Jeff Craven

Dec 18th, 2019 - ATLANTA – Use of high-concentration topical capsaicin was associated with reduced pain, a longer duration of clinical response, and was well tolerated in patients with knee osteoarthritis, compared with lower concentrations of capsaicin and placebo, according to recent research presented at the annual meeting of the American College of Rheumatology. Jeff Craven/MDedge News Tim Warneke While the.

Hydroxychloroquine prevents congenital heart block recurrence in anti-Ro pregnancies
https://www.mdedge.com/internalmedicine/article/214451/lupus-connective-tissue-diseases/hydroxychloroquine-prevents?channel=290
M. Alexander Otto

Dec 17th, 2019 - ATLANTA – Hydroxychloroquine (Plaquenil) 400 mg/day starting by pregnancy week 10 reduces recurrence of congenital heart block in infants born to women with anti-Ro antibodies, according to an open-label, prospective study presented at the annual meeting of the American College of Rheumatology. M.

ACR and EULAR release first classification criteria for IgG4-related disease
https://www.mdedge.com/internalmedicine/article/214448/lupus-connective-tissue-diseases/acr-and-eular-release-first?channel=290
Jeff Craven

Dec 17th, 2019 - The American College of Rheumatology and the European League Against Rheumatism have released the first classification criteria for IgG4-related disease. Although it was first recognized as a distinct disease in 2003, investigators have since learned that IgG4-related disease (IgG4-RD) is not particularly rare.

VEDOSS study describes predictors of progression to systemic sclerosis
https://www.mdedge.com/dermatology/article/214179/lupus-connective-tissue-diseases/vedoss-study-describes-predictors?channel=39313
Jeff Craven

Dec 12th, 2019 - ATLANTA – Patients with Raynaud’s phenomenon and puffy fingers, disease-specific antibodies, and/or nailfold video capillaroscopy abnormalities were more likely to progress to systemic sclerosis within 5 years than were patients without those features, according to recent results from the Very Early Diagnosis Of Systemic Sclerosis (VEDOSS) study presented at the annual meeting of the American C.

ADA2 is a potent new biomarker for macrophage activation syndrome
https://www.mdedge.com/fedprac/article/214103/pediatrics/ada2-potent-new-biomarker-macrophage-activation-syndrome?channel=285
M. Alexander Otto

Dec 11th, 2019 - ATLANTA – Adenosine deaminase 2 above the upper limit of normal is 86% sensitive and 94% specific for distinguishing macrophage activation syndrome from active systemic juvenile idiopathic arthritis, making it perhaps the most potent blood marker yet identified to differentiate the two, according to a report presented at the annual meeting of the American College of Rheumatology. Dr.

Tofacitinib improves disease activity in patients with polyarticular-course JIA
https://www.mdedge.com/fedprac/article/214064/pediatrics/tofacitinib-improves-disease-activity-patients-polyarticular?channel=285
Jeff Craven

Dec 11th, 2019 - ATLANTA – Treatment of polyarticular-course juvenile idiopathic arthritis with tofacitinib led to significantly fewer disease flares and greater improvement in disease activity than with placebo in a phase 3, multinational, randomized, double-blind, controlled withdrawal study presented at the annual meeting of the American College of Rheumatology. Jeff Craven/MDedge News Dr.

Repeat LTBI testing best in patients taking biologics with new risk factors
https://www.mdedge.com/fedprac/article/213923/rheumatoid-arthritis/repeat-ltbi-testing-best-patients-taking-biologics-new?channel=234
Jeff Craven

Dec 9th, 2019 - ATLANTA – Patients taking biologics who received latent tuberculosis testing on an annual basis were unlikely to convert from a negative QuantiFERON test to a positive result, which suggests that the test may be unnecessary for patients without new tuberculosis risk factors, according to research presented at the annual meeting of the American College of Rheumatology. In addition, nearly all of.

Perioperative antirheumatic drug use does not impact postsurgery infection rate in RA patients
https://www.mdedge.com/jcomjournal/article/213883/rheumatoid-arthritis/perioperative-antirheumatic-drug-use-does-not-impact?channel=302
Jeff Craven

Dec 9th, 2019 - ATLANTA – Patients with rheumatoid arthritis were more at risk of postoperative infection because of a high Charlson Comorbidity Index or longer surgery time than because of perioperative use of antirheumatic medications, according to a presentation at the annual meeting of the American College of Rheumatology. Jeff Craven/MDedge News Dr.

Updated gout guidelines: Don’t let kidney function dictate allopurinol dosing
https://www.mdedge.com/clinicianreviews/article/213863/gout/updated-gout-guidelines-dont-let-kidney-function-dictate?channel=53
M. Alexander Otto

Dec 9th, 2019 - ATLANTA – Soon-to-be-published gout guidelines from the American College of Rheumatology will recommend dosing allopurinol above 300 mg/day to get serum urate below 6 mg/dL, even in people with renal impairment. M.

Evidence grows for early axSpA treatment, uveitis flare prevention
https://www.mdedge.com/rheumatology/article/213740/ankylosing-spondylitis/evidence-grows-early-axspa-treatment-uveitis?channel=299
Denis Poddubnyy, MD

Dec 6th, 2019 - The findings from the C-axSpAnd study that Jonathan Kay, MD, and colleagues reported at the annual meeting of the American College of Rheumatology are not surprising. Earlier studies in patients with ankylosing spondylitis showed that short symptom duration is one of the best predictors of good treatment response to TNFi therapy.

Upadacitinib doubles ASAS 40 response vs. placebo in ankylosing spondylitis
https://www.mdedge.com/internalmedicine/article/213422/ankylosing-spondylitis/upadacitinib-doubles-asas-40-response-vs?channel=53
Sharon Worcester

Dec 3rd, 2019 - ATLANTA – Upadacitinib (Rinvoq), a selective Janus kinase 1 (JAK1) inhibitor, significantly improved the signs and symptoms of active ankylosing spondylitis, compared with placebo, in the randomized, placebo-controlled, phase 2/3 SELECT-AXIS 1 study. Dr.

Tanezumab posts higher safety event rate than NSAIDs over 1 year in hip, knee OA
https://www.mdedge.com/rheumatology/article/213000/osteoarthritis/tanezumab-posts-higher-safety-event-rate-nsaids-over-1?channel=53
Jeff Craven

Nov 25th, 2019 - ATLANTA – Patients with moderate to severe osteoarthritis of the hip and knee who took the investigational anti-nerve growth factor monoclonal antibody tanezumab experienced a significantly higher rate of joint safety events than that of patients who received NSAIDs as part of a recent randomized, double-blind, active-controlled, phase 3 study. Jeff Craven/MDedge News Dr.

Large population-based study underscores link between gout, CVD event risk
https://www.mdedge.com/cardiology/article/212979/gout/large-population-based-study-underscores-link-between-gout-cvd-event?channel=39313
Sharon Worcester

Nov 23rd, 2019 - ATLANTA – Gout is associated with an increased risk of both fatal and nonfatal cardiovascular disease events, according to a large population-based health data linkage study in New Zealand. Sharon Worcester/MDedge News Dr.

SPIRIT-H2H results confirm superiority of ixekizumab over adalimumab for PsA
https://www.mdedge.com/rheumatology/psoriatic-arthritis-resource-center/article/212887/psoriatic-arthritis/spirit-h2h?channel=281
Sharon Worcester

Nov 21st, 2019 - ATLANTA – Ixekizumab (Taltz) provided significantly greater improvement in joint and skin symptoms, compared with adalimumab (Humira), in biologic-naive patients with active psoriatic arthritis (PsA), according to final 52-week safety and efficacy results from the randomized SPIRIT-H2H study. Dr.

COAST-X top-line results: Ixekizumab improves nonradiographic axSpA vs. placebo
https://www.mdedge.com/rheumatology/article/212841/ankylosing-spondylitis/coast-x-top-line-results-ixekizumab-improves?channel=53
Sharon Worcester

Nov 21st, 2019 - ATLANTA – Adding ixekizumab (Taltz) to conventional background medications significantly improved the signs and symptoms of nonradiographic axial spondyloarthritis (axSpA) in the randomized, double-blind, placebo-controlled phase 3 COAST-X trial. Sharon Worcester/MDedge News Dr.

Fewer people are dying from systemic sclerosis at younger ages
https://www.mdedge.com/internalmedicine/article/212836/lupus-connective-tissue-diseases/fewer-people-are-dying-systemic?channel=290
Jeff Craven

Nov 21st, 2019 - ATLANTA – Patients with systemic sclerosis aged 44 years and younger in the United States now have mortality comparable to that of the general population in that age group, according to recent results presented at the annual meeting of the American College of Rheumatology. Dr.

Rituximab tops azathioprine for relapsing ANCA-associated vasculitis remission maintenance
https://www.mdedge.com/internalmedicine/article/212794/lupus-connective-tissue-diseases/rituximab-tops-azathioprine?channel=290
M. Alexander Otto

Nov 21st, 2019 - ATLANTA – Rituximab (Rituxan) is superior to azathioprine (Imuran) for preventing ANCA-associated vasculitis relapses in patients with histories of previous relapses, according to a randomized trial of 170 patients presented at the annual meeting of the American College of Rheumatology. Dr.

Biologic DMARDs appear as effective in elderly-onset RA as in young-onset RA
https://www.mdedge.com/rheumatology/article/212492/rheumatoid-arthritis/biologic-dmards-appear-effective-elderly-onset-ra?channel=53
Sharon Worcester

Nov 18th, 2019 - ATLANTA – Elderly-onset and young-onset rheumatoid arthritis patients initiating treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) respond similarly with respect to clinical improvement at 48 weeks and adverse events, data from a large registry in Japan suggest. Sharon Worcester/MDedge News Dr.

PREVENT trial shows benefits of secukinumab for nonradiographic axSpA
https://www.mdedge.com/internalmedicine/article/212409/ankylosing-spondylitis/prevent-trial-shows-benefits-secukinumab?channel=39313
Jeff Craven

Nov 15th, 2019 - ATLANTA – Patients with nonradiographic axial spondyloarthritis who received secukinumab with or without loading doses showed improvements in physical function, quality of life, inflammation, and other disease signs and symptoms, according to results from a phase 3 study presented at the annual meeting of the American College of Rheumatology. Jeff Craven/MDedge News Dr.

Marked increase in psoriasis seen with TNFi use in pediatric inflammatory diseases
https://www.mdedge.com/rheumatology/article/212202/pediatrics/marked-increase-psoriasis-seen-tnfi-use-pediatric?channel=53
M. Alexander Otto

Nov 13th, 2019 - ATLANTA – Tumor necrosis factor inhibitors almost quadrupled the risk of psoriasis in children with inflammatory bowel disease, juvenile idiopathic arthritis, or chronic nonbacterial osteomyelitis in a review of 4,111 patients at the Children’s Hospital of Philadelphia. Dr.

Cost-effectiveness of Duloxetine for Knee OA Patients Whose Pain Can’t Be Controlled by NSAIDs
https://acrabstracts.org/abstract/cost-effectiveness-of-duloxetine-for-knee-oa-patients-whose-pain-cant-be-controlled-by-nsaids/
James Sullivan, Jeffrey Katz 2 and Elena Losina, Brigham and Women's Hospital et. al.

Nov 13th, 2019 - Background/Purpose: Knee OA is a disabling condition affecting over 14 million adults in the US. NSAIDs provide only short-term pain relief, creating the need for additional pain management. Growing evidence indicates that chronic knee OA pain is associated with centralized pain pathways. Based on these considerations, ACR and OARSI recommend or conditionally recommend the use of duloxetine. Th...

Clinical and Functional Outcomes Among Rheumatoid Arthritis Patients Switching Between JAK1-Selective Inhibitor Upadacitinib and Adalimumab Following Insufficient Response
https://acrabstracts.org/abstract/clinical-and-functional-outcomes-among-rheumatoid-arthritis-patients-switching-between-jak1-selective-inhibitor-upadacitinib-and-adalimumab-following-insufficient-response/
Roy Fleischmann, Mark Genovese, Ricardo Blanco et. al.

Nov 13th, 2019 - Background/Purpose: The goal of RA treatment is to achieve clinical remission or, at minimum, low disease activity (LDA). Modification of initial csDMARD therapy with the addition of a biologic (b) DMARD, such as a tumor necrosis factor inhibitor (TNFi), or Janus Kinase inhibitor (JAKi) may be needed following an inadequate response (IR).1 Switches in mechanism of action have been advocated in ...

Cannabis Use Among Patients in a Large US Rheumatic Disease Registry
https://acrabstracts.org/abstract/cannabis-use-among-patients-in-a-large-us-rheumatic-disease-registry/
Kristin Wipfler, Teresa Simon, Patricia Katz et. al.

Nov 13th, 2019 - Background/Purpose: Legalization of cannabis use is rapidly increasing worldwide, raising the need to evaluate trends and medical implications. A systematic literature review showed inconsistent results on tolerability and safety of cannabis-based medicines for any chronic pain [1]. Additionally, little is known about the use and effectiveness of cannabis in rheumatic diseases [2]. We sought to...

Baseline Clinical and Serological Findings in Pediatric-Onset Discoid Lupus Erythematosus: Analysis of a Multicenter Retrospective Cohort Study
https://acrabstracts.org/abstract/baseline-clinical-and-serological-findings-in-pediatric-onset-discoid-lupus-erythematosus-analysis-of-a-multicenter-retrospective-cohort-study/
Nnenna Ezeh, Kevin Buhr, Cordellia Nguyen et. al.

Nov 13th, 2019 - Background/Purpose: DLE is a rare, disfiguring disorder in children. Small retrospective studies suggest 20-25% of patients progress to SLE. Progression risk factors are poorly understood, but DLE has been associated with delay in SLE diagnosis and reduced access to care. This multicenter retrospective cohort study aimed to describe baseline characteristics and clinical phenotypes of pediatric ...

Model-based Cost-Effectiveness Analyses Comparing Combinations of Urate Lowering Therapy and Anti-Inflammatory Treatment in Newly Diagnosed Gout Patients
https://acrabstracts.org/abstract/model-based-cost-effectiveness-analyses-comparing-combinations-of-urate-lowering-therapy-and-anti-inflammatory-treatment-in-newly-diagnosed-gout-patients/
Celine van de Laar, Martijn A.H. Oude Voshaar, Carly Janssen et. al.

Nov 13th, 2019 - Background/Purpose: To assess the cost-effectiveness of various combinations of urate lowering therapy (ULT) and anti-inflammatory treatment in the management of newly diagnosed gout patients, from the Dutch societal perspective.  Methods: The Anakinra versus Treatment as usual in the Treatment of ACute Gout (ATTACG) study was the  primary data source for  this study.  Since only patients with ...

Machine-learning Classification Identifies a Subset of Patients That Improve on Abatacept via Modulation of a CD28-Related Pathway
https://acrabstracts.org/abstract/machine-learning-classification-identifies-a-subset-of-patients-that-improve-on-abatacept-via-modulation-of-a-cd28-related-pathway/
Bhaven Mehta, Jennifer Franks, Yiwei Yuan et. al.

Nov 13th, 2019 - Background/Purpose: We analyzed a phase 2 study designed to assess the efficacy of abatacept in patients with diffuse Systemic Sclerosis (SSc). In this work, we analyze data from ASSET and seek to confirm the hypothesis that patients in the inflammatory subset on abatacept show a significant decline in modified Rodnan Skin Score (mRSS), which is correlated to modulation of pathways related to t...

Metabolic Signatures of Pathogenic T Cells in Medium and Large Vessel Vasculitis
https://acrabstracts.org/abstract/metabolic-signatures-of-pathogenic-t-cells-in-medium-and-large-vessel-vasculitis/
Mitsuhiro Akiyama, Hui Zhang, Ryu Watanabe et. al.

Nov 13th, 2019 - Background/Purpose: Giant cell arteritis (GCA) is an autoimmune vasculitis that causes aortic arch syndrome, blindnesss, and stroke. Embedded in granulomatous infiltrates, CD4 T cells persist over long periods in the inflamed vessel wall where they drive wall remodeling, intramural neoangiogenesis, intimal hyperplasia and luminal occulsion. To survive and function in a nonlymphoid tissue enviro...

The Role of Bradykinin Receptor B1 and Its New Ligand Soluble CD13 in Rheumatoid Arthritis and Inflammatory Arthritis Mouse Model
https://acrabstracts.org/abstract/the-role-of-bradykinin-receptor-b1-and-its-new-ligand-soluble-cd13-in-rheumatoid-arthritis-and-inflammatory-arthritis-mouse-model/
Chenyang Lu, Phillip Campbell, Jonatan Hervoso et. al.

Nov 13th, 2019 - Background/Purpose: Rheumatoid arthritis (RA) is an inflammatory disorder characterized by synovial hyperplasia, inflammatory cell infiltration and pannus formation. We have shown that soluble CD13 (sCD13) induces angiogenesis, monocyte and lymphocyte chemotaxis and arthritis through G protein-coupled receptors (GPCRs). However, the receptor for sCD13 is not yet defined. Methods: A GPCR screeni...

Lung-Related Factors Are Associated with Transitions from Systemic Anti-CCP Antibody Positivity to Classified RA
https://acrabstracts.org/abstract/lung-related-factors-are-associated-with-transitions-from-systemic-anti-ccp-antibody-positivity-to-classified-ra/
Ashley Visser, Marie Feser, Chelsie Fleischer et. al.

Nov 13th, 2019 - Background/Purpose: Systemic autoimmunity associated with RA precedes the onset of inflammatory arthritis (IA) by several years. In particular, the presence of systemic anti-cyclic citrullinated peptide (CCP) antibody is a strong predictor of developing classified RA in the future. However, the mechanisms involved in the transition from systemic anti-CCP to IA classifiable as RA are unknown. Ou...

Nocturnal Blood Pressure Dipping as a Marker of Endothelial and Cardiac Function in Pediatric-onset Systemic Lupus Erythematosus
https://acrabstracts.org/abstract/nocturnal-blood-pressure-dipping-as-a-marker-of-endothelial-and-cardiac-function-in-pediatric-onset-systemic-lupus-erythematosus/
Joyce Chang, Taylor Goldberg, Sarah McGuire et. al.

Nov 13th, 2019 - Background/Purpose: There is a need for clinically useful measures of cardiovascular (CV) risk in pediatric-onset SLE (pSLE). Nocturnal blood pressure (BP) non-dipping (loss of the physiologic nocturnal decline in BP) is a reversible marker of CV risk and potential treatment target that can be reproducibly measured by ambulatory blood pressure monitoring (ABPM). We assessed the frequency of non...

Knee Injury and Transitions Among States of Knee Osteoarthritis in the Johnston County Osteoarthritis Project: A Multi-State Time-To-Event Modeling Approach
https://acrabstracts.org/abstract/knee-injury-and-transitions-among-states-of-knee-osteoarthritis-in-the-johnston-county-osteoarthritis-project-a-multi-state-time-to-event-modeling-approach/
Yvonne Golightly, Carolina Alvarez, Liubov Arbeeva et. al.

Nov 13th, 2019 - Background/Purpose: Musculoskeletal injury is a known risk factor for osteoarthritis (OA). Cumulative effects of comorbid conditions on the association of injury and OA have not been previously examined. The purpose of this study was to clarify associations between knee injury and radiographic knee osteoarthritis (rKOA) and determine whether associations vary by sex, race, body mass index (BMI)...

Ancestry-Specific Classical HLA Alleles Define Phenotypic Subsets in the African American Scleroderma Population
https://acrabstracts.org/abstract/ancestry-specific-classical-hla-alleles-define-phenotypic-subsets-in-the-african-american-scleroderma-population/
Pravitt Gourh, Sarah Safran, Steven Boyden et. al.

Nov 13th, 2019 - Background/Purpose: Systemic sclerosis (SSc), or scleroderma, is a heterogeneous disease that is divided into limited cutaneous (lcSSc) and diffuse cutaneous (dcSSc) forms based on the extent of skin involvement, and internal organ involvement also adds to phenotypic variability. The three main internal organ complications are interstitial lung disease (ILD), pulmonary arterial hypertension (PA...

Geographic Disparities in Systemic Sclerosis Mortality in the United States: 1999 to 2017
https://acrabstracts.org/abstract/geographic-disparities-in-systemic-sclerosis-mortality-in-the-united-states-1999-to-2017/
Alicia Rodriguez-Pla1 and Robert W Simms, University of Arizona/Banner Health Medical Center, Tucson et. al.

Nov 13th, 2019 - Background/Purpose: Population mortality studies in the United States have previously reported a progressive increase in the scleroderma (SSc) mortality rates from 1959 to 2002. Identification of areas with clusters of higher mortality rates is important to implement targeted interventions and may provide clues about possible etiology factors, especially environmental. In this study, we aimed t...

Go-Dact: A Phase 3b Randomized Double-Blind Placebo-Controled Proof-Of-Concept Trial, of Golimumab Plus Methotrexate (MTX) versus MTX Monotherapy, in Improving Dactylitis, in MTX Naïve Psoriatic Ar...
https://acrabstracts.org/abstract/go-dact-a-phase-3b-randomized-double-blind-placebo-controled-proof-of-concept-trial-of-golimumab-plus-methotrexate-mtx-versus-mtx-monotherapy-in-improving-dactylitis-in-mtx-naive-psoriatic-arthr/
Elsa Vieira-Sousa, Pedro Alves, Ana Maria Rodrigues et. al.

Nov 13th, 2019 - Background/Purpose: Psoriatic arthritis (PsA) dactylitis is associated with an increased risk of erosions and higher disease activity. Dactylitis treatment strategies are however controversial due to the absence of evidence from randomized controlled trials studying dactylitis as a primary outcome. The objective of this trial was to assess the efficacy of golimumab in combination with methotrex...

Increased Expression of Extracellular Matrix Proteins in Human Fibroblast Synoviocytes and Lung Epithelial Cells Following Malondialdehyde-Acetaldehyde Adduct (MAA)/Citrullinated Protein Stimulation
https://acrabstracts.org/abstract/increased-expression-of-extracellular-matrix-proteins-in-human-fibroblast-synoviocytes-and-lung-epithelial-cells-following-malondialdehyde-acetaldehyde-adduct-maa-citrullinated-protein-stimulation/
Matthew O'Dell, Logan Duryee, Lynell Klassen et. al.

Nov 13th, 2019 - Background/Purpose: Recently we have shown that both malondialdehyde-acetaldehyde adducts (MAA) and citrullinated proteins (CIT) are co-localized in joint and lung tissues of patients with rheumatoid arthritis (RA). Therefore, to investigate the possibility that these post-translational modifications pose a synergistic pathogenic role in RA, human synovial fibroblasts and lung epithelial cells ...

Long-term Clinical and Economic Benefits of a Short-term Physical Activity Intervention Among Inactive Knee Osteoarthritis Patients in US: A Model-based Evaluation
https://acrabstracts.org/abstract/long-term-clinical-and-economic-benefits-of-a-short-term-physical-activity-intervention-among-inactive-knee-osteoarthritis-patients-in-us-a-model-based-evaluation/
Genevieve Silva, James Sullivan, Jeffrey Katz et. al.

Nov 13th, 2019 - Background/Purpose: The United States (US) knee osteoarthritis (OA) population has low levels of physical activity (PA), despite its well-defined health benefits. Interventions to promote PA are often stymied by concerns of lack of sustainability of intervention efficacy. We sought to evaluate lifetime benefits and cost-effectiveness of a short term (3-year) PA intervention in this population. ...

Serum Interferon Score Predicts Clinical Outcome at 12 Months in Diffuse Cutaneous Systemic Sclerosis as Measured by Global Ranked Composite Score (GRCS) and Composite Response Index in SSc (CRISS)
https://acrabstracts.org/abstract/serum-interferon-score-predicts-clinical-outcome-at-12-months-in-diffuse-cutaneous-systemic-sclerosis-as-measured-by-global-ranked-composite-score-grcs-and-composite-response-index-in-ssc-criss/
Antonio Carriero, Giuseppina Abignano, MIchelle Hutchinson et. al.

Nov 13th, 2019 - Background/Purpose: Systemic sclerosis (SSc) is a highly heterogeneous disease orphan of effective disease modifying agents. The diffuse cutaneous clinical subset (dcSSc) is currently targeted in most clinical trials. Nevertheless, there is still high variability in clinical outcome within dcSSc, which is limiting effective clinical trial design and interpretation. Global Ranked Composite Score...

Comparison of Malignancy and Mortality Rates Between Tofacitinib and Biologic DMARDs in Clinical Practice: Five-Year Results from a US-Based Rheumatoid Arthritis Registry
https://acrabstracts.org/abstract/comparison-of-malignancy-and-mortality-rates-between-tofacitinib-and-biologic-dmards-in-clinical-practice-five-year-results-from-a-us-based-rheumatoid-arthritis-registry/
Joel Kremer, Clifton Bingham, Laura Cappelli et. al.

Nov 13th, 2019 - Background/Purpose: Real-world evidence (RWE) is key to understanding post-approval long-term safety of medications. Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. A prospective observational 5-year study, embedded within the US Corrona RA registry, was initiated to evaluate the safety of tofacitinib after US Food and Drug Administration approval on Nov 6, 2012. The obje...